Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

En studie för att lära sig mer om hur säkert BAY 3771249 är och hur väl det fungerar hos personer med avancerad eller metastaserad kolorektalcancer som har en KRAS G12D-mutation

1 oktober 2026 uppdaterad av: Bayer

Masterprotokoll: En öppen studie för att utvärdera säkerheten, tolerabiliteten, farmakokinetiken, farmakodynamiken och effekten av BAY 3771249 som monoterapi eller i kombination med andra cancerbehandlingar hos deltagare med solida tumörer som bär på en KRAS G12D-mutation Substudieprotokoll: En öppen, flerkohortstudie för att utvärdera säkerheten, tolerabiliteten, farmakokinetiken, farmakodynamiken och preliminär antitumöraktivitet av BAY 3771249 som monoterapi och i kombination med cetuximab hos deltagare med avancerad/metastaserad kolorektal adenokarcinom som bär på en KRAS G12D-mutation

Researchers are looking for a better way to treat people who have advanced or metastatic colorectal cancer (CRC) with a specific mutation, the G12D mutation, in a protein called KRAS.

Colorectal cancer (CRC) is a common type of cancer that affects the large bowel (colon) or the rectum (the section at the end of the bowel). When CRC spreads to other parts of the body, it is called advanced or metastatic CRC. Some people with CRC have the G12D mutation in the KRAS protein. This mutation is linked to a poorer outlook and fewer treatment options. Currently, there are no approved treatments that specifically target this mutation.

KRAS is a protein that helps control how cells grow and divide. When it is mutated, it can cause cells to grow uncontrollably, leading to cancer. The study drug, BAY 3771249, is designed to block the activity of KRAS with G12D mutation, which may help slow or stop the growth of cancer cells. BAY 3771249 can be given alone or together with another drug called cetuximab.

The main purpose of this study is to learn how safe BAY 3771249 is, how well people tolerate it, how the body processes the drug, and whether it can help shrink or control tumors in people with advanced or metastatic CRC that has the KRAS G12D mutation. The study will also look at how BAY 3771249 works when given alone or with cetuximab, especially in people who have already tried other treatments for their cancer.

Researchers will measure, among others:

The number and seriousness of health problems (adverse events) after receiving BAY 3771249.

The number of participants who experience a dose-limiting side effect (DLT) at each dose level.

The number of participants whose tumors shrink or disappear (overall response rate, ORR) as measured by standard criteria.

How much of the drug is in the blood over time (AUC) and the highest amount in the blood (Cmax).

Some participants will receive BAY 3771249 alone (monotherapy), and others will receive BAY 3771249 with cetuximab (combination therapy).

The study will start with lower doses and gradually increase to find the highest safe dose (dosage escalation). After the safe dose is found, more participants may join the study to receive it (dosage expansion). In some parts of the study, participants may be randomly assigned to different groups or doses. The study is open-label, meaning both participants and doctors know which treatment is being given.

An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events, even if they do not think it is related to the study treatment.

The study doctors and their team will contact participants to learn about their health until they complete the study.

If a participant benefits from the treatment, it might be possible to continue receiving BAY 3771249 after the end of the study. The findings from this study may help develop a new treatment option for people with advanced or metastatic CRC with a KRAS G12D mutation.

Studieöversikt

Studietyp

Interventionell

Inskrivning (Beräknad)

130

Fas

  • Fas 1

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studieorter

    • New South Wales
      • Albury, New South Wales, Australien, 2640
        • Har inte rekryterat ännu
        • Border Medical oncology - Albury Wodonga Regional Cancer Centre
      • Waratah, New South Wales, Australien, 2298
        • Rekrytering
        • Calvary Mater Hospital Newcastle - Oncology
    • Victoria
      • Malvern, Victoria, Australien, 3144
        • Har inte rekryterat ännu
        • Cabrini Health Oncology Research
    • East Flanders
      • Ghent, East Flanders, Belgien, 9000
        • Har inte rekryterat ännu
        • Ghent University Hospital | Drug Research Unit Department
    • Capital Region / Region Hovedstaden
      • Copenhagen, Capital Region / Region Hovedstaden, Danmark, 2100
        • Har inte rekryterat ännu
        • Rigshospitalet Copenhagen University Hospital | Oncology Department
    • Region of Southern Denmark / Region Syddanmark
      • Odense, Region of Southern Denmark / Region Syddanmark, Danmark, 5000
        • Har inte rekryterat ännu
        • Odense University Hospital | Svendborg Sygehus - Oncology Department
    • Uusimaa
      • Helsinki, Uusimaa, Finland, 00029
        • Har inte rekryterat ännu
        • HUS-Yhtymä, Helsingin yliopistollinen sairaala (HUS) - Syöpäkeskus
    • Arizona
      • Phoenix, Arizona, Förenta staterna, 85054
        • Har inte rekryterat ännu
        • Mayo Clinic - Cancer Center - Phoenix
    • California
      • Duarte, California, Förenta staterna, 91010
        • Rekrytering
        • City of Hope - Duarte Cancer Center
      • San Diego, California, Förenta staterna, 92037
        • Har inte rekryterat ännu
        • UC San Diego Health - Moores Cancer Center
    • Colorado
      • Denver, Colorado, Förenta staterna, 80218
        • Indragen
        • Sarah Cannon Research Institute at HCA HealthONE Presbyterian St. Luke's
    • New York
      • New York, New York, Förenta staterna, 10029
        • Har inte rekryterat ännu
        • Icahn School of Medicine at Mount Sinai - Oncology
    • Texas
      • Irving, Texas, Förenta staterna, 75039
        • Rekrytering
        • NEXT Dallas - Oncology Department
      • San Antonio, Texas, Förenta staterna, 78229
        • Rekrytering
        • START | San Antonio
      • Roma, Italien, 00128
        • Har inte rekryterat ännu
        • Fondazione Policlinico Universitario Agostino Gemelli IRCCS - UOC Fase I
    • North Holland
      • Amsterdam, North Holland, Nederländerna, 1066 CX
        • Har inte rekryterat ännu
        • Nederlands Kanker Instituut
      • Singapore, Singapore, 119074
        • Rekrytering
        • National University Hospital Medical Centre
      • Singapore, Singapore, 168583
        • Rekrytering
        • National Cancer Center Singapore - Oncology Department
    • Barcelona
      • Barcelona, Barcelona, Spanien, 08035
        • Har inte rekryterat ännu
        • Hospital Universitari Vall D Hebron | Oncologia
    • Madrid
      • Madrid, Madrid, Spanien, 28050
        • Har inte rekryterat ännu
        • Hospital Universitario Hm Sanchinarro | Oncologia
    • Stockholm County
      • Stockholm, Stockholm County, Sverige, 171 76
        • Har inte rekryterat ännu
        • Karolinska Universitetssjukhuset - Solna - Fas I-enheten Solna CKC

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • KRAS G12D mutated solid tumor
  • Participant must be ≥18 years old or the legal age of consent in the jurisdiction in which the study is taking place when signing the screening ICF
  • At least one measurable lesion as per RECIST v1.1. outside the CNS
  • Eastern Cooperative Oncology Group performance status (ECOG PS) of ≤1
  • Male or Female: Contraceptive use by participant or participant's partners should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
  • Life expectancy of at least 3 months in the opinion of the Investigator
  • Histologically/pathologically documented diagnosis of advanced/metastatic adenocarcinoma of the colon and rectum.
  • Adequate hematologic and end-organ function

Exclusion Criteria:

  • Leptomeningeal disease or carcinomatous meningiti
  • Uncontrolled and/or active/symptomatic brain metastases.
  • Significant traumatic injury or major surgical procedure within 4 weeks of first dose of study intervention
  • Known hypersensitivity to any component of study intervention
  • Previous (within 3 years) or concurrent cancer that is distinct in primary site or histology from the cancer being evaluated in the respective substudy.
  • Active infection requiring systemic anti-infective therapy within 14 days of first dose of study intervention
  • Known HIV infection
  • Active Hepatitis B virus (HBV) infection
  • Active Hepatitis C virus (HCV) infection
  • Significant cardiac disorder
  • History of risk factors for torsade de pointes (TdP) (e.g., heart failure, family history of long QT syndrome)
  • Participants with inadequately managed diabetes as assessed by the Investigator
  • Toxicities from prior anticancer therapy, defined as not having resolved to Grade ≤1 or as specified in the respective substudy protocol as per NCI CTCAE v.6.0 with the following exceptions: Alopecia of any grade, Peripheral neuropathy Grade ≤2, Autoimmune endocrine disorders Grade ≤2 managed with stable endocrine replacement therapy
  • History of (non-infectious) pneumonitis/interstitial lung disease (ILD), drug-induced ILD, radiation pneumonitis (unless it has resolved without sequelae without use of steroids), or any evidence of clinically-active pneumonitis/ILD
  • History of the following eye disorders: keratitis, ulcerative keratitis

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: N/A
  • Interventionsmodell: Sekventiell tilldelning
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Dosage escalation

In the dosage escalation part, different dose levels of BAY 3771249 administered as monotherapy and in combination with cetuximab are planned.

Oral

Intravenous (IV) infusion

Experimentell: Dosage expansion

In the dosage expansion part, participants will receive BAY 3771249 either as monotherapy or in combination with cetuximab until disease progression as defined by RECIST v1.1, the occurrence of unacceptable toxicity, or the fulfillment of any other withdrawal criteria.

Oral

Intravenous (IV) infusion

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Change from baseline in laboratory test results
Tidsram: Up to approximately 2 years

Hematology, serum chemistry, urinalysis and coagulation tests. Applicable in Dosage escalation and expansion

Up to approximately 2 years
Change from baseline in vital signs: Blood pressure
Tidsram: Up to approximately 2 years

Applicable in Dosage escalation and expansion

Up to approximately 2 years
Change from baseline in vital signs: Body temperature
Tidsram: Up to approximately 2 years

Applicable in Dosage escalation and expansion

Up to approximately 2 years
Change from baseline in vital signs: Oxygen saturation
Tidsram: Up to approximately 2 years

Applicable in Dosage escalation and expansion

Up to approximately 2 years
Change from baseline in vital signs: Pulse rate
Tidsram: Up to approximately 2 years

Applicable in Dosage escalation and expansion

Up to approximately 2 years
Change from baseline in vital signs: Respiratory rate
Tidsram: Up to approximately 2 years

Applicable in Dosage escalation and expansion

Up to approximately 2 years
Number of participants experiencing a dose-limiting toxicity (DLT) at each dosage
Tidsram: Up to approximately 3 weeks

Applicable in Dose escalation part

Up to approximately 3 weeks
Number of participants with Treatment-emergent adverse events (TEAEs)
Tidsram: Up to approximately 2 years.

Applicable in Dosage escalation and expansion

Up to approximately 2 years.
Objective response rate (ORR) as determined by the Investigator according to RECIST v1.1
Tidsram: Up to approximately 2 years

Applicable in Dosage escalation and expansion

Up to approximately 2 years
Severity of TEAEs
Tidsram: Up to approximately 2 years.

Applicable in Dosage escalation and expansion

Up to approximately 2 years.

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Pharmacokinetics (PK) parameters such as area under the concentration vs time curve (AUC)
Tidsram: Up to approximately 2 years

Applicable in Dosage escalation

Up to approximately 2 years
PK parameters such as maximum observed drug concentration (Cmax)
Tidsram: Up to approximately 2 years

Applicable in Dosage escalation

Up to approximately 2 years

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

7 april 2026

Primärt slutförande (Beräknad)

27 juli 2029

Avslutad studie (Beräknad)

9 juli 2030

Studieregistreringsdatum

Först inskickad

1 april 2026

Först inskickad som uppfyllde QC-kriterierna

9 april 2026

Första postat (Faktisk)

16 april 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

5 oktober 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

1 oktober 2026

Senast verifierad

1 oktober 2026

Mer information

Termer relaterade till denna studie

Andra studie-ID-nummer

  • 23111-1
  • 2025 (U.S.S. NIH-anslag/kontrakt)
  • 2025-523648-11-00 (Ctis)

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

IPD-planbeskrivning

Currently, there is no established plan for the sharing of Individual Patient Data (IPD) from this study. The availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA 'Principles for responsible clinical trial data sharing.' This pertains to the scope, timepoint, and process of data access. As such, Bayer commits to considering requests from qualified researchers for patient- / study-level clinical trial data, and documents from clinical trials involving medicines and indications approved in the US and EU. However, this commitment does not reflect an active IPD sharing plan. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Researchers can use www.vivli.org to request access to IPD and documents from clinical studies to conduct research. Information on Bayer's criteria for listing studies is provided in the member section of the portal.

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Ja

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera